Diniz Carmen Simone Grilo, Franzon Ana Carolina Arruda, Fioretti-Foschi Beatriz, Niy Denise Yoshie, Pedrilio Livia Sanches, Amaro Edson, Sato João Ricardo
School of Public Health, University of Sao Paulo, Sao Paulo, Brazil.
Programa de Apoio ao Desenvolvimento Institucional do Sistema Único de Saúde, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
JMIR Res Protoc. 2021 May 21;10(5):e25016. doi: 10.2196/25016.
In Brazil and other low- and middle-income countries, excess interventions in childbirth are associated with an increase in preterm and early-term births, contributing to stagnant morbidity and mortality of mothers and neonates. The fact that women often report a negative experience with vaginal childbirth, with physical pain and feelings of unsafety, neglect, or abuse, may explain the high acceptability of elective cesarean sections. The recognition of information needs and of the right to informed choice during childbirth can help change this reality. The internet has been the main source of health information, but its quality is highly variable.
This study aimed to develop and evaluate an information and communication strategy through a smartphone app with respect to childbirth, to facilitate informed choices for access to safer and evidence-based care in the context of the COVID-19 pandemic.
A randomized controlled trial, with 2 arms (intervention and control) and a closed, blind, parallel design, will be conducted with a smartphone app designed for behavior and opinion research in Brazil, with women of reproductive age previously registered on the app. After completing an entry questionnaire to verify the eligibility criteria and obtaining ethical consent, approximately 20,000 participants will be randomly allocated to the intervention and control groups at a 1:1 ratio. Participants allocated to the intervention group will be invited to engage in a digital information and communication strategy, which is designed to expand evidence-based knowledge on the advantages and disadvantages of options for labor and childbirth and the safety of the care processes. The information is based on the guidelines of the Ministry of Health and the World Health Organization for a positive childbirth experience and has been updated to include the new challenges and disruptions in maternity care within the context of the COVID-19 pandemic. The control group will receive information regarding disposable and reusable diapers as a placebo intervention. The groups will be compared in their responses in generating the birth plan and the entry and exit questionnaires, regarding responses less or more aligned with the guidelines for a positive childbirth experience. A qualitative component to map information needs is included.
The digital trial started recruiting participants in late October 2020, and data collection has been projected to be complete by December 2020.
This study will evaluate an innovative intervention that has the potential to promote better communication between women and providers, such that they can make better choices using an approach suitable for use during the COVID-19 pandemic.
The Brazilian Clinical Trials Registry U1111-1255-8683; http://www.ensaiosclinicos.gov.br/rg/RBR-3g5f9f/.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/25016.
在巴西以及其他低收入和中等收入国家,分娩时的过度干预与早产和早期足月产的增加相关,导致母亲和新生儿的发病率和死亡率停滞不前。女性经常报告阴道分娩有负面经历,包括身体疼痛以及不安全、被忽视或受虐待的感觉,这可能解释了选择性剖宫产的高接受度。认识到分娩期间的信息需求和知情选择的权利有助于改变这一现实。互联网一直是健康信息的主要来源,但其质量差异很大。
本研究旨在开发并评估一款通过智能手机应用程序提供的有关分娩的信息和沟通策略,以便在2019冠状病毒病大流行背景下,为获得更安全且基于证据的护理提供知情选择便利。
将采用一款为巴西行为和意见研究设计的智能手机应用程序,对2组(干预组和对照组)进行随机对照试验,采用封闭、盲法、平行设计,参与对象为之前已在该应用程序上注册的育龄女性。在完成一份用于核实纳入标准的入组问卷并获得伦理同意后,约20000名参与者将按1:1的比例随机分配至干预组和对照组。分配至干预组的参与者将被邀请参与一项数字信息和沟通策略,该策略旨在扩展关于分娩方式的优缺点及护理过程安全性的基于证据的知识。这些信息基于巴西卫生部和世界卫生组织关于积极分娩体验的指南,并已更新,以纳入2019冠状病毒病大流行背景下产科护理的新挑战和干扰因素。对照组将接受关于一次性和可重复使用尿布的信息作为安慰剂干预。将比较两组在制定分娩计划以及入组和退出问卷中的回答,看哪些回答与积极分娩体验指南的契合程度更高或更低。还纳入了一个用于梳理信息需求的定性部分。
该数字试验于2020年10月下旬开始招募参与者,预计数据收集将于2020年12月完成。
本研究将评估一项创新干预措施,该措施有可能促进女性与医护人员之间更好的沟通,使她们能够采用适合在2019冠状病毒病大流行期间使用的方法做出更好的选择。
巴西临床试验注册中心U1111 - 1255 - 第八章683;http://www.ensaiosclinicos.gov.br/rg/RBR - 3g5f9f/。
国际注册报告标识号(IRRID):PRR1 - 10.2196/25016。